| 1 |
34638362 | Expression Patterns of TOP2A and SIRT1 Are Predictive of Survival in Patients with High-Risk Soft Tissue Sarcomas Treated with a Neoadjuvant Anthracycline-Based Chemotherapy. | 2021 Sep 29 |
1 |
| 2 |
32780321 | Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer. | 2020 Nov |
3 |
| 3 |
28800016 | FISH Analysis of TOP2A and HER-2 Aberrations in Female Breast Carcinoma on Archived Material: Egyptian NCI Experience. | 2019 Mar |
1 |
| 4 |
31301170 | Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines. | 2019 Jul 12 |
1 |
| 5 |
29516929 | Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer. | 2018 Jan-Mar |
3 |
| 6 |
29728799 | Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy. | 2018 Jul |
2 |
| 7 |
29752560 | Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review. | 2018 May 11 |
1 |
| 8 |
27530622 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. | 2017 May |
1 |
| 9 |
28393224 | Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer. | 2017 May |
1 |
| 10 |
28432084 | Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer. | 2017 Jul |
1 |
| 11 |
29323058 | Assessment of topoisomerase II-alpha gene status by dual color chromogenic in situ hybridization in a set of Iraqi patients with invasive breast carcinoma. | 2017 Oct-Dec |
1 |
| 12 |
25710584 | The Predictive and Prognostic Role of Topoisomerase IIα and Tissue Inhibitor of Metalloproteinases 1 Expression in Locally Advanced Breast Carcinoma of Egyptian Patients Treated With Anthracycline-based Neoadjuvant Chemotherapy. | 2016 Mar |
1 |
| 13 |
26867764 | A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. | 2016 Feb 11 |
2 |
| 14 |
27127018 | Adjuvant chemotherapy in early breast cancer. | 2016 May |
2 |
| 15 |
27503929 | Chromatin-Remodeling Complex SWI/SNF Controls Multidrug Resistance by Transcriptionally Regulating the Drug Efflux Pump ABCB1. | 2016 Oct 1 |
1 |
| 16 |
27799773 | Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer. | 2016 |
2 |
| 17 |
27821228 | [Abnormality of TOP2A expression and its gene copy number variations in neuroblastic tumors]. | 2016 Nov 8 |
1 |
| 18 |
25777966 | Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers. | 2015 Jun |
1 |
| 19 |
25897160 | Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. | 2015 May 20 |
3 |
| 20 |
24682655 | HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. | 2014 May |
1 |
| 21 |
25042383 | Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer. | 2014 Oct |
3 |
| 22 |
25379022 | Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. | 2014 Oct |
1 |
| 23 |
25406834 | Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. | 2014 Nov 18 |
1 |
| 24 |
25642443 | The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset. | 2014 Dec |
5 |
| 25 |
25693082 | Topoisomerase 2α status in invasive breast carcinoma - comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation. | 2014 Dec |
2 |
| 26 |
23222298 | Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs. | 2013 Jan 15 |
1 |
| 27 |
23537287 | Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. | 2013 Mar 28 |
2 |
| 28 |
24072219 | DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. | 2013 |
2 |
| 29 |
24106899 | TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. | 2013 Oct |
1 |
| 30 |
24138107 | Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer. | 2013 Dec |
2 |
| 31 |
21681601 | Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy. | 2012 Jan |
2 |
| 32 |
22042366 | Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. | 2012 Jan |
2 |
| 33 |
22153616 | Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. | 2012 Feb |
1 |
| 34 |
22160637 | TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. | 2012 Feb |
1 |
| 35 |
22204715 | Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. | 2012 Sep |
1 |
| 36 |
22240029 | HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. | 2012 Jan 12 |
2 |
| 37 |
22374418 | Topoisomerase 2 alpha: a real predictor of anthracycline efficacy? | 2012 Mar |
1 |
| 38 |
22864769 | TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. | 2012 Sep |
5 |
| 39 |
23092535 | Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. | 2012 Oct 23 |
4 |
| 40 |
21189395 | Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. | 2011 Mar 1 |
5 |
| 41 |
21422418 | Multifactorial approach to predicting resistance to anthracyclines. | 2011 Apr 20 |
1 |
| 42 |
21519837 | Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. | 2011 Jul |
1 |
| 43 |
21734419 | Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. | 2011 |
3 |
| 44 |
21917518 | HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. | 2011 Nov |
2 |
| 45 |
22016618 | The important molecular markers on chromosome 17 and their clinical impact in breast cancer. | 2011 |
1 |
| 46 |
19657712 | Predictive factors for anthracycline-based chemotherapy for human breast cancer. | 2010 Apr |
6 |
| 47 |
19767729 | Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. | 2010 Jan |
1 |
| 48 |
19795206 | Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. | 2010 Jan |
1 |
| 49 |
20052594 | Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. | 2010 Jul |
1 |
| 50 |
20079691 | Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). | 2010 Mar |
1 |